KEJADIAN REINFARK MIOKARD AKIBAT ANTIKOAGULAN UFH DAN ENOXAPARIN PASIEN STEMI
DOI:
https://doi.org/10.35730/jk.v12i1.436Abstract
Secara farmakologis enoxaparin lebih baik dibanding UFH dalam mengobati pasien STEMI karena lebih sedikit mengaktivasi trombosit. Aktivasi trombosit ini kemudian memicu terjadi reinfark miokard. Tujuan penelitian ini untuk mengetahui perbedaan kejadian reinfark miokard pada pasien STEMI yang menggunakan antikoagulan UFH dan enoxaparin. Metode penelitian ini menggunakan systematic review, yakni metode yang digunakan untuk mengumpulkan bukti-bukti relevan, sesuai dengan kriteria kelayakan yang sudah ditentukan sebelumnya untuk menjawab pertanyaan penelitian yang menjadi fokus peneliti. Penilaian kualitas jurnal menggunakan The Cochrane Collaboration’s Tool for Assessing Risk of Bias. Total 36.778 pasien STEMI mendapat terapi antikoagulan, 18.385 menggunakan enoxaparin dan 18.383 menggunakan UFH atau heparin. Pasien yang mendapat terapi fibrinolitik lain sebagai tatalaksana STEMI sebelumnya sebanyak 23.255 pasien, kemudian dirandomisasi untuk mendapat terapi enoxaparin atau heparin. Terdapat perbedaan kejadian reinfark miokard akibat penggunaan antikoagulan UFH dan enoxaparin namun tidak pada pasien yang mendapat terapi inisial UFH. Enoxaparin direkomendasikan sebagai antikoagulan pilihan untuk digunakan dalam menatalaksana pasien STEMI.
References
Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Pedoman Tata Laksana Sindrom Koroner Akut, Keempat. 2018.
World Health Organization, “Fact Sheets Cardiovascular disease (CVDs),†2017. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
S. Ali-Hassan-Sayegh et al., “Administration of low molecular weight and unfractionated heparin during percutaneous coronary intervention,†Indian Heart J., vol. 68, no. 2, pp. 213–224, 2016, doi: 10.1016/j.ihj.2016.01.014.
A. Katoh and H. Ikeda, “Platelet count as a prognostic marker in patients with acute coronary syndromes,†Circ. J., vol. 76, no. 3, pp. 591–592, 2012, doi: 10.1253/circj.CJ-12-0053.
B. S. Salter et al., “Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review,†J. Am. Coll. Cardiol., vol. 67, no. 21, pp. 2519–2532, 2016, doi: 10.1016/j.jacc.2016.02.073.
V. Auffret et al., “Efficacité et sécurité d’emploi de l’administration pré-hospitalière d’héparine non fractionnée, d’énoxaparine ou de bivalirudine chez des patients présentant un syndrome coronarien aigu avec sus-décalage persistant du segment ST traités par angioplastie primaire : données du registre ORBI,†Arch. Cardiovasc. Dis., vol. 109, no. 12, pp. 696–707, 2016, doi: 10.1016/j.acvd.2015.10.007.
Y. J. Li et al., “Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents,†J. Cardiol., vol. 59, no. 1, pp. 22–29, 2012, doi: 10.1016/j.jjcc.2011.09.005.
M. Cohen et al., “The Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI): A Randomized Trial,†J. Am. Coll. Cardiol., vol. 42, no. 8, pp. 1348–1356, 2003, doi: 10.1016/S0735-1097(03)01040-4.
M. S. Sabatine et al., “Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With ST-Segment Elevation Myocardial Infarction Also Treated With Clopidogrel,†J. Am. Coll. Cardiol., vol. 49, no. 23, pp. 2256–2263, 2007, doi: 10.1016/j.jacc.2007.01.092.
M. El-Rayes et al., “Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-Quebec registry,†Can. J. Cardiol., vol. 26, no. 8, pp. 431–436, 2010, doi: 10.1016/S0828-282X(10)70441-4.
R. R. Giraldez et al., “Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: An ExTRACT-TIMI 25 analysis,†Eur. Heart J., vol. 28, no. 13, pp. 1566–1573, 2007, doi: 10.1093/eurheartj/ehm179.
S. H. Baird, I. B. A. Menown, S. J. McBride, T. G. Trouton, and C. Wilson, “Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction,†Eur. Heart J., vol. 23, no. 8, pp. 627–632, 2002, doi: 10.1053/euhj.2001.2940.
T. H. Tjay and K. Rahardja, Obat-Obat Penting, Khasiat, Penggunaan dan Efek-Efek Samping, VII. Jakarta: PT Elex Media Komputindo, 2015.
M. S. Sabatine et al., “Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 trial,†Circulation, vol. 112, no. 25, pp. 3846–3854, 2005, doi: 10.1161/CIRCULATIONAHA.105.595397.
A. Rubboli, “Efficacy and Safety of Low-Molecular-Weight Heparins As An Adjunct to Thrombolysis in Acute ST-Elevation Myocardial Infarction,†Curr. Cardiol. Rev., vol. 4, no. 1, pp. 63–71, 2008, doi: 10.2174/157340308783565438.
J. W. Eikelboom, D. J. Quinlan, S. R. Mehta, A. G. Turpie, I. B. Menown, and S. Yusuf, “Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: A meta-analysis of the randomized trials,†Circulation, vol. 112, no. 25, pp. 3855–3867, 2005, doi: 10.1161/CIRCULATIONAHA.105.573550.
S. Singh, A. Bahekar, J. Molnar, S. Khosla, and R. Arora, “Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized control trials,†Clin. Cardiol., vol. 32, no. 7, pp. 358–364, 2009, doi: 10.1002/clc.20432.
G. S. Lavi S, Cantor WJ, Casanova A, Tan MK, Yan AT, DžavÃk V, Fitchett D, Cohen EA, Borgundvaag B, Heffernan M, Ducas J, “Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial,†Am. Heart J., vol. 163, no. 2, pp. 176–181, 2012, [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/22305834/.
B. Katzung, Basic & Clinical Pharmacology, 14th editi. McGraw-Hill Education, 2018.
Z. A. Onwordi ENC, Gamal A, “Anticoagulant therapy for acute coronary syndromes,†Interv. Cardiol. Rev., vol. 13, no. 2, pp. 87–92, 2018, [Online]. Available: https://www.icrjournal.com/articles/anticoagulant-therapy-acute-coronary.
D. P. Dunn SP, Cardiology B-A, Kazmi H, Cardiology Critical Care Antithrombotic Therapies in Acute Coronary Syndrome. Ccsap, 2017.
